{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,16]],"date-time":"2026-09-16T08:00:40Z","timestamp":1789545640477,"version":"build-2803163510"},"reference-count":84,"publisher":"MDPI AG","issue":"11","license":[{"start":{"date-parts":[[2023,11,19]],"date-time":"2023-11-19T00:00:00Z","timestamp":1700352000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Pharmaceuticals"],"abstract":"<jats:p>In multiple myeloma impressive outcomes have improved with the introduction of new therapeutic approaches, mainly those including naked monoclonal antibodies such as daratumumab and isatuximab. However, moving to earlier lines of therapy with effective anti-myeloma drugs led to an increase in the number of patients who developed multi-refractoriness to them early on. Currently, triple- or multi-refractory MM represents an unmet medical need, and their management remains a complicated challenge. The recent approval of new immunotherapeutic approaches such as conjugated monoclonal antibodies, bispecific antibodies, and CAR T cells could be a turning point for these heavily pretreated patients. Nevertheless, several issues regarding their use are unsolved, such as how to select patients for each strategy or how to sequence these therapies within the MM therapeutic landscape. Here we provide an overview of the most recent data about approved conjugated monoclonal antibody belantamab, mafodotin, bispecific antibody teclistamab, and other promising compounds under development, mainly focusing on the ongoing clinical trials with monoclonal antibody combination approaches in advanced and earlier phases of MM treatment.<\/jats:p>","DOI":"10.3390\/ph16111628","type":"journal-article","created":{"date-parts":[[2023,11,20]],"date-time":"2023-11-20T00:30:50Z","timestamp":1700440250000},"page":"1628","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":18,"title":["Novel Immunotherapies and Combinations: The Future Landscape of Multiple Myeloma Treatment"],"prefix":"10.3390","volume":"16","author":[{"given":"Sonia","family":"Mor\u00e8","sequence":"first","affiliation":[{"name":"Clinica di Ematologia Azienda Ospedaliero Universitaria delle Marche, 60126 Ancona, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Laura","family":"Corvatta","sequence":"additional","affiliation":[{"name":"U.O.C. Medicina, Ospedale Profili, 60044 Fabriano, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Valentina Maria","family":"Manieri","sequence":"additional","affiliation":[{"name":"Clinica di Ematologia Azienda Ospedaliero Universitaria delle Marche, 60126 Ancona, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Erika","family":"Morsia","sequence":"additional","affiliation":[{"name":"Clinica di Ematologia Azienda Ospedaliero Universitaria delle Marche, 60126 Ancona, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Antonella","family":"Poloni","sequence":"additional","affiliation":[{"name":"Clinica di Ematologia Azienda Ospedaliero Universitaria delle Marche, 60126 Ancona, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2749-7347","authenticated-orcid":false,"given":"Massimo","family":"Offidani","sequence":"additional","affiliation":[{"name":"Clinica di Ematologia Azienda Ospedaliero Universitaria delle Marche, 60126 Ancona, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1968","published-online":{"date-parts":[[2023,11,19]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","first-page":"1046","DOI":"10.1056\/NEJMra1011442","article-title":"Multiple Myeloma","volume":"364","author":"Palumbo","year":"2011","journal-title":"N. Engl. J. Med."},{"key":"ref_2","doi-asserted-by":"crossref","first-page":"660","DOI":"10.1182\/blood-2018-09-825331","article-title":"Toward Personalized Treatment in Multiple Myeloma Based on Molecular Characteristics","volume":"133","author":"Pawlyn","year":"2019","journal-title":"Blood"},{"key":"ref_3","doi-asserted-by":"crossref","first-page":"38","DOI":"10.1097\/PPO.0000000000000356","article-title":"Cellular Immunotherapy for Multiple Myeloma","volume":"25","author":"Rosenblatt","year":"2019","journal-title":"Cancer J."},{"key":"ref_4","doi-asserted-by":"crossref","first-page":"271","DOI":"10.2147\/tcrm.2006.2.3.271","article-title":"Bortezomib (Velcadetrade Mark) in the Treatment of Multiple Myeloma","volume":"2","author":"Morgan","year":"2006","journal-title":"Ther. Clin. Risk Manag."},{"key":"ref_5","doi-asserted-by":"crossref","first-page":"920","DOI":"10.2174\/1871520616666160902101622","article-title":"Second Generation Proteasome Inhibitors in Multiple Myeloma","volume":"17","author":"Gozzetti","year":"2017","journal-title":"Anticancer. Agents Med. Chem."},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"198","DOI":"10.1111\/bjh.14780","article-title":"Recent Progress in Relapsed Multiple Myeloma Therapy: Implications for Treatment Decisions","volume":"179","author":"Moreau","year":"2017","journal-title":"Br. J. Haematol."},{"key":"ref_7","doi-asserted-by":"crossref","unstructured":"D\u2019Agostino, M., Innorcia, S., Boccadoro, M., and Bringhen, S. (2020). Monoclonal Antibodies to Treat Multiple Myeloma: A Dream Come True. Int. J. Mol. Sci., 21.","DOI":"10.3390\/ijms21218192"},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"7297","DOI":"10.1182\/blood-2022-163494","article-title":"Daratumumab Plus Lenalidomide and Dexamethasone (D-Rd) Versus Lenalidomide and Dexamethasone (Rd) in Transplant-Ineligible Patients (Pts) with Newly Diagnosed Multiple Myeloma (NDMM): Clinical Assessment of Key Subgroups of the Phase 3 Maia Study","volume":"140","author":"Moreau","year":"2022","journal-title":"Blood"},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1016\/S0140-6736(19)31240-1","article-title":"Bortezomib, Thalidomide, and Dexamethasone with or without Daratumumab before and after Autologous Stem-Cell Transplantation for Newly Diagnosed Multiple Myeloma (CASSIOPEIA): A Randomised, Open-Label, Phase 3 Study","volume":"394","author":"Moreau","year":"2019","journal-title":"Lancet"},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"e890","DOI":"10.1016\/S2352-3026(23)00236-3","article-title":"Minimal Residual Disease Response-Adapted Therapy in Newly Diagnosed Multiple Myeloma (MASTER): Final Report of the Multicentre, Single-Arm, Phase 2 Trial","volume":"10","author":"Costa","year":"2023","journal-title":"Lancet Haematol."},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"2901","DOI":"10.1200\/JCO.21.01935","article-title":"Daratumumab, Carfilzomib, Lenalidomide, and Dexamethasone With Minimal Residual Disease Response-Adapted Therapy in Newly Diagnosed Multiple Myeloma","volume":"40","author":"Costa","year":"2022","journal-title":"J. Clin. Oncol."},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"1096852","DOI":"10.3389\/fonc.2022.1096852","article-title":"Experts\u2019 Consensus on the Definition and Management of High Risk Multiple Myeloma","volume":"12","author":"Marcon","year":"2023","journal-title":"Front. Oncol."},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"432","DOI":"10.1111\/bjh.18658","article-title":"Real-World Assessment of Treatment Patterns and Outcomes in Patients with Relapsed-Refractory Multiple Myeloma in an Italian Haematological Tertiary Care Centre","volume":"201","author":"Corvatta","year":"2023","journal-title":"Br. J. Haematol."},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"1541","DOI":"10.1158\/1078-0432.CCR-19-2111","article-title":"V How to Train Your T Cells: Overcoming Immune Dysfunction in Multiple Myeloma","volume":"26","author":"Cohen","year":"2020","journal-title":"Clin. Cancer Res."},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"S3","DOI":"10.1002\/ajh.25418","article-title":"An Introduction to Chimeric Antigen Receptor (CAR) T-Cell Immunotherapy for Human Cancer","volume":"94","author":"Feins","year":"2019","journal-title":"Am. J. Hematol."},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"651","DOI":"10.1182\/blood-2021-145572","article-title":"Universal Updated Phase 1 Data Validates the Feasibility of Allogeneic Anti-BCMA ALLO-715 Therapy for Relapsed\/Refractory Multiple Myeloma","volume":"138","author":"Mailankody","year":"2021","journal-title":"Blood"},{"key":"ref_17","doi-asserted-by":"crossref","first-page":"185","DOI":"10.1038\/s41573-019-0051-2","article-title":"\u201cOff-the-Shelf\u201d Allogeneic CAR T Cells: Development and Challenges","volume":"19","author":"Depil","year":"2020","journal-title":"Nat. Rev. Drug Discov."},{"key":"ref_18","doi-asserted-by":"crossref","first-page":"158","DOI":"10.1158\/2767-9764.CRC-21-0157","article-title":"Allogeneic Anti-BCMA CAR T Cells Are Superior to Multiple Myeloma-Derived CAR T Cells in Preclinical Studies and May Be Combined with Gamma Secretase Inhibitors","volume":"2","author":"Metelo","year":"2022","journal-title":"Cancer Res. Commun."},{"key":"ref_19","doi-asserted-by":"crossref","first-page":"69","DOI":"10.1053\/j.seminoncol.2022.01.004","article-title":"Harnessing Natural Killer Cells for the Treatment of Multiple Myeloma","volume":"49","author":"Clara","year":"2022","journal-title":"Semin. Oncol."},{"key":"ref_20","doi-asserted-by":"crossref","unstructured":"Kleber, M., Ntanasis-Stathopoulos, I., and Terpos, E. (2021). BCMA in Multiple Myeloma-A Promising Key to Therapy. J. Clin. Med., 10.","DOI":"10.3390\/jcm10184088"},{"key":"ref_21","doi-asserted-by":"crossref","first-page":"85","DOI":"10.1016\/j.ddtec.2018.08.005","article-title":"Amanitins and Their Development as a Payload for Antibody-Drug Conjugates","volume":"30","author":"Pahl","year":"2018","journal-title":"Drug Discov. Today Technol."},{"key":"ref_22","doi-asserted-by":"crossref","first-page":"3128","DOI":"10.1182\/blood-2013-10-535088","article-title":"Novel Anti-B-Cell Maturation Antigen Antibody-Drug Conjugate (GSK2857916) Selectively Induces Killing of Multiple Myeloma","volume":"123","author":"Tai","year":"2014","journal-title":"Blood"},{"key":"ref_23","doi-asserted-by":"crossref","first-page":"125","DOI":"10.1186\/s13045-020-00962-7","article-title":"BCMA-Targeted Immunotherapy for Multiple Myeloma","volume":"13","author":"Yu","year":"2020","journal-title":"J. Hematol. Oncol."},{"key":"ref_24","doi-asserted-by":"crossref","first-page":"231","DOI":"10.1146\/annurev.immunol.21.120601.141152","article-title":"BAFF and APRIL: A Tutorial on B Cell Survival","volume":"21","author":"Mackay","year":"2003","journal-title":"Annu. Rev. Immunol."},{"key":"ref_25","doi-asserted-by":"crossref","first-page":"3835","DOI":"10.1038\/s41467-019-11680-1","article-title":"Genomic Landscape and Chronological Reconstruction of Driver Events in Multiple Myeloma","volume":"10","author":"Maura","year":"2019","journal-title":"Nat. Commun."},{"key":"ref_26","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1177\/2515135518763280","article-title":"Bispecific Antibodies in Cancer Immunotherapy","volume":"6","year":"2018","journal-title":"Ther. Adv. Vaccines Immunother."},{"key":"ref_27","doi-asserted-by":"crossref","first-page":"290","DOI":"10.1038\/icb.2014.93","article-title":"Bispecific T-Cell Engagers for Cancer Immunotherapy","volume":"93","author":"Huehls","year":"2015","journal-title":"Immunol. Cell Biol."},{"key":"ref_28","doi-asserted-by":"crossref","first-page":"2203","DOI":"10.1158\/1078-0432.CCR-19-2299","article-title":"Preclinical Activity of JNJ-7957, a Novel BCMA\u00d7CD3 Bispecific Antibody for the Treatment of Multiple Myeloma, Is Potentiated by Daratumumab","volume":"26","author":"Frerichs","year":"2020","journal-title":"Clin. Cancer Res."},{"key":"ref_29","doi-asserted-by":"crossref","first-page":"985","DOI":"10.1038\/s41375-020-0734-z","article-title":"B-Cell Maturation Antigen (BCMA) in Multiple Myeloma: Rationale for Targeting and Current Therapeutic Approaches","volume":"34","author":"Shah","year":"2020","journal-title":"Leukemia"},{"key":"ref_30","doi-asserted-by":"crossref","unstructured":"Ross, S.L., Sherman, M., McElroy, P.L., Lofgren, J.A., Moody, G., Baeuerle, P.A., Coxon, A., and Arvedson, T. (2017). Bispecific T Cell Engager (BiTE\u00ae) Antibody Constructs Can Mediate Bystander Tumor Cell Killing. PLoS ONE, 12.","DOI":"10.1371\/journal.pone.0183390"},{"key":"ref_31","doi-asserted-by":"crossref","first-page":"57","DOI":"10.1097\/FTD.0000000000000668","article-title":"Key Features Defining the Disposition of Bispecific Antibodies and Their Efficacy In Vivo","volume":"42","author":"Golay","year":"2020","journal-title":"Ther. Drug Monit."},{"key":"ref_32","doi-asserted-by":"crossref","first-page":"1821","DOI":"10.3389\/fimmu.2018.01821","article-title":"Targeting B Cell Maturation Antigen (BCMA) in Multiple Myeloma: Potential Uses of BCMA-Based Immunotherapy","volume":"9","author":"Cho","year":"2018","journal-title":"Front. Immunol."},{"key":"ref_33","doi-asserted-by":"crossref","first-page":"1196","DOI":"10.1056\/NEJMoa2209900","article-title":"GPRC5D-Targeted CAR T Cells for Myeloma","volume":"387","author":"Mailankody","year":"2022","journal-title":"N. Engl. J. Med."},{"key":"ref_34","doi-asserted-by":"crossref","first-page":"eaau7746","DOI":"10.1126\/scitranslmed.aau7746","article-title":"GPRC5D Is a Target for the Immunotherapy of Multiple Myeloma with Rationally Designed CAR T Cells","volume":"11","author":"Smith","year":"2019","journal-title":"Sci. Transl. Med."},{"key":"ref_35","doi-asserted-by":"crossref","first-page":"7333","DOI":"10.1038\/ncomms8333","article-title":"\u03b3-Secretase Directly Sheds the Survival Receptor BCMA from Plasma Cells","volume":"6","author":"Laurent","year":"2015","journal-title":"Nat. Commun."},{"key":"ref_36","doi-asserted-by":"crossref","first-page":"383","DOI":"10.1016\/j.ccell.2017.02.001","article-title":"Membrane-Proximal Epitope Facilitates Efficient T Cell Synapse Formation by Anti-FcRH5\/CD3 and Is a Requirement for Myeloma Cell Killing","volume":"31","author":"Li","year":"2017","journal-title":"Cancer Cell"},{"key":"ref_37","doi-asserted-by":"crossref","first-page":"7301","DOI":"10.1182\/blood-2022-164877","article-title":"Single-Agent Belantamab Mafodotin in Patients with Relapsed or Refractory Multiple Myeloma: Final Analysis of the DREAMM-2 Trial","volume":"140","author":"Nooka","year":"2022","journal-title":"Blood"},{"key":"ref_38","doi-asserted-by":"crossref","first-page":"e801","DOI":"10.1016\/S2352-3026(23)00243-0","article-title":"Efficacy and safety of single-agent belantamab mafodotin versus pomalidomide plus low-dose dexamethasone in patients with relapsed or refractory multiple myeloma (DREAMM-3): A phase 3, open-label, randomised study","volume":"10","author":"Dimopoulos","year":"2023","journal-title":"Lancet Haematol."},{"key":"ref_39","doi-asserted-by":"crossref","first-page":"830","DOI":"10.1097\/01.HS9.0000846628.17113.b2","article-title":"Safety and Clinical Activity of Belantamab Mafodotin with Pembrolizumab in Patients with Relapsed \/ Refractory Multiple Myeloma (RRMM): DREAMM-4 Study","volume":"6","author":"Suvannasankha","year":"2022","journal-title":"HemaSphere"},{"key":"ref_40","doi-asserted-by":"crossref","first-page":"e9722122","DOI":"10.1097\/01.HS9.0000970556.97221.22","article-title":"Low-dose belantamab mafodotin (belamaf) in combination with nirogacestat vs belamaf monotherapy in patients with relapsed\/refractory multiple myeloma (RRMM): Phase1\/2 DREAMM-5 platform sub-study 3","volume":"7","author":"Callander","year":"2023","journal-title":"HemaSphere"},{"key":"ref_41","doi-asserted-by":"crossref","first-page":"831","DOI":"10.1097\/01.HS9.0000846632.03623.af","article-title":"Safety and clinical activity of belantamab mafodotin with lenalidomide plus dexamethasone in patients with relapsed\/refractory multiple myeloma (RRMM). OMM): DREAMM-6 arm-A interim analysis. I","volume":"6","author":"Quach","year":"2022","journal-title":"HemaSphere"},{"key":"ref_42","doi-asserted-by":"crossref","first-page":"8018","DOI":"10.1200\/JCO.2023.41.16_suppl.8018","article-title":"A Phase 1 Study of Belantamab Mafodotin in Combination with Standard of Care in Newly Diagnosed Multiple Myeloma: An Interim Analysis of DREAMM-9","volume":"41","author":"Usmani","year":"2023","journal-title":"J. Clin. Oncol."},{"key":"ref_43","doi-asserted-by":"crossref","first-page":"797","DOI":"10.1038\/s41573-019-0034-3","article-title":"Adaptive Platform Trials: Definition, Design, Conduct and Reporting Considerations","volume":"18","author":"Angus","year":"2019","journal-title":"Nat. Rev. Drug Discov."},{"key":"ref_44","doi-asserted-by":"crossref","first-page":"7306","DOI":"10.1182\/blood-2022-160445","article-title":"Belantamab Mafodotin in Combination with Pomalidomide and Dexamethasone Demonstrates Durable Responses in Triple Class Exposed\/Refractory Multiple Myeloma","volume":"140","author":"Trudel","year":"2022","journal-title":"Blood"},{"key":"ref_45","doi-asserted-by":"crossref","first-page":"8011","DOI":"10.1200\/JCO.2023.41.16_suppl.8011","article-title":"Long-Term Follow-up from MajesTEC-1 of Teclistamab, a B-Cell Maturation Antigen (BCMA) x CD3 Bispecific Antibody, in Patients with Relapsed\/Refractory Multiple Myeloma (RRMM)","volume":"41","author":"Moreau","year":"2023","journal-title":"J. Clin. Oncol."},{"key":"ref_46","doi-asserted-by":"crossref","first-page":"e306","DOI":"10.1038\/bcj.2015.32","article-title":"The Cellular Immune System in Myelomagenesis: NK Cells and T Cells in the Development of Myeloma [Corrected] and Their Uses in Immunotherapies","volume":"5","author":"Dosani","year":"2015","journal-title":"Blood Cancer J."},{"key":"ref_47","doi-asserted-by":"crossref","first-page":"e162590","DOI":"10.1097\/01.HS9.0000970364.16259.0e","article-title":"Teclistamab in combination with lenalidomide in previously treated patients with multiple myeloma in the phase 1B multicohort Majestec-2 study","volume":"7","author":"Tan","year":"2023","journal-title":"HemaSphere"},{"key":"ref_48","doi-asserted-by":"crossref","first-page":"e1257964","DOI":"10.1097\/01.HS9.0000967688.12579.64","article-title":"Teclistamab (TEC) + nirogacestat (NIRO) in relapsed\/refractory multiple myeloma (RRMM): The phase 1B Majestec-2 study","volume":"7","author":"Offner","year":"2023","journal-title":"HemaSphere"},{"key":"ref_49","doi-asserted-by":"crossref","first-page":"2570","DOI":"10.1038\/s41591-023-02589-w","article-title":"Elranatamab in Relapsed or Refractory Multiple Myeloma: The MagnetisMM-1 Phase 1 Trial","volume":"29","author":"Bahlis","year":"2023","journal-title":"Nat. Med."},{"key":"ref_50","doi-asserted-by":"crossref","first-page":"2259","DOI":"10.1038\/s41591-023-02528-9","article-title":"Elranatamab in Relapsed or Refractory Multiple Myeloma: Phase 2 MagnetisMM-3 Trial Results","volume":"29","author":"Lesokhin","year":"2023","journal-title":"Nat. Med."},{"key":"ref_51","doi-asserted-by":"crossref","first-page":"8040","DOI":"10.1200\/JCO.2023.41.16_suppl.8040","article-title":"Efficacy and Safety of Elranatamab by Age and Frailty in Patients (Pts) with Relapsed\/Refractory Multiple (RRMM): A Subgroup Analysis from MagnetisMM-3","volume":"41","author":"Raje","year":"2023","journal-title":"J. Clin. Oncol."},{"key":"ref_52","doi-asserted-by":"crossref","first-page":"6618","DOI":"10.1200\/JCO.2023.41.16_suppl.6618","article-title":"An Indirect Comparison of Elranatamab\u2019s (ELRA) Objective Response Rate (ORR) from MagnetisMM-3 (MM-3) vs Real-World External Control Arms in Triple-Class Refractory (TCR) Multiple Myeloma (MM)","volume":"41","author":"Costa","year":"2023","journal-title":"J. Clin. Oncol."},{"key":"ref_53","doi-asserted-by":"crossref","first-page":"e20038","DOI":"10.1200\/JCO.2023.41.16_suppl.e20038","article-title":"A Matching-Adjusted Indirect Treatment Comparison of Elranatamab in Patients with Triple-Class Exposed Relapsed\/Refractory Multiple Myeloma: Comparisons with Belantamab Mafodotin, Selinexor plus Dexamethasone, and Real-World Physician\u2019s Choice of Treatmen","volume":"41","author":"Hlavacek","year":"2023","journal-title":"J. Clin. Oncol."},{"key":"ref_54","doi-asserted-by":"crossref","first-page":"8006","DOI":"10.1200\/JCO.2023.41.16_suppl.8006","article-title":"LINKER-MM1 Study: Linvoseltamab (REGN5458) in Patients with Relapsed\/Refractory Multiple Myeloma","volume":"41","author":"Lee","year":"2023","journal-title":"J. Clin. Oncol."},{"key":"ref_55","doi-asserted-by":"crossref","first-page":"2196","DOI":"10.1182\/bloodadvances.2020003805","article-title":"Preclinical Activity and Determinants of Response of the GPRC5DxCD3 Bispecific Antibody Talquetamab in Multiple Myeloma","volume":"5","author":"Verkleij","year":"2021","journal-title":"Blood Adv."},{"key":"ref_56","doi-asserted-by":"crossref","first-page":"2232","DOI":"10.1056\/NEJMoa2204591","article-title":"Talquetamab, a T-Cell\u2013Redirecting GPRC5D Bispecific Antibody for Multiple Myeloma","volume":"387","author":"Chari","year":"2022","journal-title":"N. Engl. J. Med."},{"key":"ref_57","doi-asserted-by":"crossref","first-page":"8036","DOI":"10.1200\/JCO.2023.41.16_suppl.8036","article-title":"Pivotal Phase 2 MonumenTAL-1 Results of Talquetamab (Tal), a GPRC5DxCD3 Bispecific Antibody (BsAb), for Relapsed\/Refractory Multiple Myeloma (RRMM)","volume":"41","author":"Schinke","year":"2023","journal-title":"J. Clin. Oncol."},{"key":"ref_58","doi-asserted-by":"crossref","first-page":"8003","DOI":"10.1200\/JCO.2023.41.16_suppl.8003","article-title":"Talquetamab (Tal) + Daratumumab (Dara) in Patients (Pts) with Relapsed\/Refractory Multiple Myeloma (RRMM): Updated TRIMM-2 Results","volume":"41","author":"Dholaria","year":"2023","journal-title":"J. Clin. Oncol."},{"key":"ref_59","doi-asserted-by":"crossref","first-page":"85","DOI":"10.1016\/j.cmet.2017.10.006","article-title":"CD38-NAD(+)Axis Regulates Immunotherapeutic Anti-Tumor T Cell Response","volume":"27","author":"Chatterjee","year":"2018","journal-title":"Cell Metab."},{"key":"ref_60","doi-asserted-by":"crossref","first-page":"8002","DOI":"10.1200\/JCO.2023.41.16_suppl.8002","article-title":"First Results from the RedirecTT-1 Study with Teclistamab (Tec) + Talquetamab (Tal) Simultaneously Targeting BCMA and GPRC5D in Patients (Pts) with Relapsed\/Refractory Multiple Myeloma (RRMM)","volume":"41","author":"Cohen","year":"2023","journal-title":"J. Clin. Oncol."},{"key":"ref_61","doi-asserted-by":"crossref","first-page":"157","DOI":"10.1182\/blood-2021-147983","article-title":"Cevostamab Monotherapy Continues to Show Clinically Meaningful Activity and Manageable Safety in Patients with Heavily Pre-Treated Relapsed\/Refractory Multiple Myeloma (RRMM): Updated Results from an Ongoing Phase I Study","volume":"138","author":"Trudel","year":"2021","journal-title":"Blood"},{"key":"ref_62","doi-asserted-by":"crossref","first-page":"4415","DOI":"10.1182\/blood-2022-157547","article-title":"Enduring Responses after 1-Year, Fixed-Duration Cevostamab Therapy in Patients with Relapsed\/Refractory Multiple Myeloma: Early Experience from a Phase I Study","volume":"140","author":"Lesokhin","year":"2022","journal-title":"Blood"},{"key":"ref_63","doi-asserted-by":"crossref","first-page":"889","DOI":"10.1007\/s40123-020-00280-8","article-title":"Corneal Epithelial Findings in Patients with Multiple Myeloma Treated with Antibody-Drug Conjugate Belantamab Mafodotin in the Pivotal, Randomized, DREAMM-2 Study","volume":"9","author":"Farooq","year":"2020","journal-title":"Ophthalmol. Ther."},{"key":"ref_64","doi-asserted-by":"crossref","first-page":"207","DOI":"10.1016\/S1470-2045(19)30788-0","article-title":"Belantamab Mafodotin for Relapsed or Refractory Multiple Myeloma (DREAMM-2): A Two-Arm, Randomised, Open-Label, Phase 2 Study","volume":"21","author":"Lonial","year":"2020","journal-title":"Lancet Oncol."},{"key":"ref_65","doi-asserted-by":"crossref","first-page":"3746","DOI":"10.1002\/cncr.34987","article-title":"Single-Agent Belantamab Mafodotin in Patients with Relapsed\/Refractory Multiple Myeloma: Final Analysis of the DREAMM-2 Trial","volume":"129","author":"Nooka","year":"2023","journal-title":"Cancer"},{"key":"ref_66","doi-asserted-by":"crossref","first-page":"188","DOI":"10.1182\/blood-2014-05-552729","article-title":"Current Concepts in the Diagnosis and Management of Cytokine Release Syndrome","volume":"124","author":"Lee","year":"2014","journal-title":"Blood"},{"key":"ref_67","doi-asserted-by":"crossref","first-page":"5154","DOI":"10.1182\/blood-2013-02-485623","article-title":"Cytokine Release Syndrome after Blinatumomab Treatment Related to Abnormal Macrophage Activation and Ameliorated with Cytokine-Directed Therapy","volume":"121","author":"Teachey","year":"2013","journal-title":"Blood"},{"key":"ref_68","doi-asserted-by":"crossref","first-page":"e255","DOI":"10.1016\/S1470-2045(23)00159-6","article-title":"Prevention and Management of Adverse Events during Treatment with Bispecific Antibodies and CAR T Cells in Multiple Myeloma: A Consensus Report of the European Myeloma Network","volume":"24","author":"Ludwig","year":"2023","journal-title":"Lancet Oncol."},{"key":"ref_69","doi-asserted-by":"crossref","first-page":"8033","DOI":"10.1200\/JCO.2023.41.16_suppl.8033","article-title":"Evaluation of Prophylactic Tocilizumab (Toci) for the Reduction of Cytokine Release Syndrome (CRS) to Inform the Management of Patients (Pts) Treated with Teclistamab in MajesTEC-1","volume":"41","author":"Garfall","year":"2023","journal-title":"J. Clin. Oncol."},{"key":"ref_70","doi-asserted-by":"crossref","first-page":"e75458a8","DOI":"10.1097\/01.HS9.0000970688.75458.a8","article-title":"Tocilizumab pre-treatment significantly reduces the incidence of cytokine release syndrome in patients with relapsed\/refractory multiple myeloma (RRMM) who receive cevostamab","volume":"7","author":"Mateos","year":"2023","journal-title":"HemaSphere"},{"key":"ref_71","doi-asserted-by":"crossref","unstructured":"Mohan, M., Chakraborty, R., Bal, S., Nellore, A., Baljevic, M., D\u2019Souza, A., Pappas, P.G., Berdeja, J.G., Callander, N., and Costa, L.J. (2023). Recommendations on Prevention of Infections during Chimeric Antigen Receptor T-Cell and Bispecific Antibody Therapy in Multiple Myeloma. Br. J. Haematol., Online ahead of print.","DOI":"10.1111\/bjh.18909"},{"key":"ref_72","doi-asserted-by":"crossref","first-page":"34","DOI":"10.1038\/s41408-023-00808-8","article-title":"Infectious Complications of Bispecific Antibody Therapy in Patients with Multiple Myeloma","volume":"13","author":"Sim","year":"2023","journal-title":"Blood Cancer J."},{"key":"ref_73","doi-asserted-by":"crossref","unstructured":"Hammons, L., Szabo, A., Janardan, A., Bhatlapenumarthi, V., Annyapu, E., Dhakal, B., Al Hadidi, S., Radhakrishnan, S.V., Narra, R., and Bhutani, D. (2023). The Changing Spectrum of Infection with BCMA and GPRC5D Targeting Bispecific Antibody (BsAb) Therapy in Patients with Relapsed Refractory Multiple Myeloma. Haematologica, Online ahead of print.","DOI":"10.3324\/haematol.2023.283590"},{"key":"ref_74","doi-asserted-by":"crossref","first-page":"495","DOI":"10.1056\/NEJMoa2203478","article-title":"Teclistamab in Relapsed or Refractory Multiple Myeloma","volume":"387","author":"Moreau","year":"2022","journal-title":"N. Engl. J. Med."},{"key":"ref_75","doi-asserted-by":"crossref","first-page":"e1309654","DOI":"10.1097\/01.HS9.0000967696.13096.54","article-title":"Elranatamab, a B-cell maturation antigen (BCMA)-CD3 bispecific antibody, for patients with relapsed\/refractory multiple myeloma: Extended follow up and biweekly administration from MagnetisMM-3","volume":"7","author":"Mohty","year":"2023","journal-title":"HemaSphere"},{"key":"ref_76","doi-asserted-by":"crossref","first-page":"3186","DOI":"10.3324\/haematol.2023.283003","article-title":"Protracted Viral Infections in Patients with Multiple Myeloma Receiving Bispecific T-Cell Engager Therapy Targeting B-Cell Maturation Antigen","volume":"108","author":"Palmen","year":"2023","journal-title":"Haematologica"},{"key":"ref_77","doi-asserted-by":"crossref","first-page":"2087","DOI":"10.1200\/JCO.22.01365","article-title":"Idecabtagene Vicleucel for Relapsed\/Refractory Multiple Myeloma: Real-World Experience From the Myeloma CAR T Consortium","volume":"41","author":"Hansen","year":"2023","journal-title":"J. Clin. Oncol."},{"key":"ref_78","doi-asserted-by":"crossref","first-page":"117","DOI":"10.1038\/s41408-023-00886-8","article-title":"Real-World Experience of Patients with Multiple Myeloma Receiving Ide-Cel after a Prior BCMA-Targeted Therapy","volume":"13","author":"Ferreri","year":"2023","journal-title":"Blood Cancer J."},{"key":"ref_79","doi-asserted-by":"crossref","first-page":"219","DOI":"10.1182\/blood.2022015526","article-title":"Efficacy and Safety of Cilta-Cel in Patients with Progressive Multiple Myeloma after Exposure to Other BCMA-Targeting Agents","volume":"141","author":"Cohen","year":"2023","journal-title":"Blood"},{"key":"ref_80","doi-asserted-by":"crossref","first-page":"756","DOI":"10.1182\/blood.2022017848","article-title":"Interventions and Outcomes of Patients with Multiple Myeloma Receiving Salvage Therapy after BCMA-Directed CAR T Therapy","volume":"141","author":"Nath","year":"2023","journal-title":"Blood"},{"key":"ref_81","doi-asserted-by":"crossref","first-page":"2295","DOI":"10.1038\/s41591-023-02491-5","article-title":"Mechanisms of Antigen Escape from BCMA- or GPRC5D-Targeted Immunotherapies in Multiple Myeloma","volume":"29","author":"Lee","year":"2023","journal-title":"Nat. Med."},{"key":"ref_82","doi-asserted-by":"crossref","first-page":"S53","DOI":"10.1016\/S2152-2650(23)01653-1","article-title":"Real world experience of patients treated with teclistamab: A BCMA-directed bispecific T-cell engaging therapy for multiple myeloma","volume":"23","author":"Midha","year":"2023","journal-title":"Clin. Lymphoma Myeloma Leuk."},{"key":"ref_83","doi-asserted-by":"crossref","unstructured":"Sanoyan, D.A., Seipel, K., Bacher, U., Kronig, M.-N., Porret, N., Wiedemann, G., Daskalakis, M., and Pabst, T. (2023). Real-Life Experiences with CAR T-Cell Therapy with Idecabtagene Vicleucel (Ide-Cel) for Triple-Class Exposed Relapsed\/Refractory Multiple Myeloma Patients. BMC Cancer, 23.","DOI":"10.1186\/s12885-023-10824-3"},{"key":"ref_84","doi-asserted-by":"crossref","first-page":"705","DOI":"10.1056\/NEJMoa2024850","article-title":"Idecabtagene Vicleucel in Relapsed and Refractory Multiple Myeloma","volume":"384","author":"Munshi","year":"2021","journal-title":"N. Engl. J. Med."}],"container-title":["Pharmaceuticals"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/1424-8247\/16\/11\/1628\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,10]],"date-time":"2025-10-10T21:25:31Z","timestamp":1760131531000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/1424-8247\/16\/11\/1628"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,11,19]]},"references-count":84,"journal-issue":{"issue":"11","published-online":{"date-parts":[[2023,11]]}},"alternative-id":["ph16111628"],"URL":"https:\/\/doi.org\/10.3390\/ph16111628","relation":{},"ISSN":["1424-8247"],"issn-type":[{"value":"1424-8247","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,11,19]]}}}